Juvenile idiopathic arthritis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments

The expanding pipeline for juvenile idiopathic arthritis can be attributed to the increase in its prevalence. One of the major factor that stimulate the growth of pipeline and research is that the cause of juvenile idiopathic arthritis is not known. The juvenile idiopathic arthritis occurs mostly in children before 16 years of age. Since the disease occurs only in children, so the safety and efficacy concerns of the drugs is given preference so that it can be treated without any side effects. Some of the other factors driving the pipeline growth include, raising awareness of health issues among children and less number of drugs available for therapy against juvenile idiopathic arthritis. Currently, one in 1,000 child in the U.S. suffers with juvenile idiopathic arthritis. Females are more susceptible to juvenile idiopathic arthritis than males.

Explore Report at: www.psmarketresearch.com/market-analysis/juvenile-idiopathic-arthritis-therapeutics-pipeline-analysis

Juvenile idiopathic arthritis can be symptomatized as swelling, joint pain, tenderness, stiffness and fever that last for approximately more than 6 weeks. Juvenile idiopathic arthritis, mostly occurs when body’s immune system erroneously attacks its own healthy tissues and cells, which result in inflammation, pain, heat, redness and swelling. Researchers have studied that, either environmental factors or genetic tendency of child act as triggers for the occurrence of the disease. Juvenile idiopathic arthritis affects mostly joints in knees, hand and feet. Sometimes, severe complication can occur in children with juvenile idiopathic arthritis such as eye inflammation. Currently, no medical test is approved for diagnosis of juvenile idiopathic arthritis. Physicians diagnose juvenile idiopathic arthritis by examining the medical history of the patient and the result of other tests that help in ruling out other morbidities.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/juvenile-idiopathic-arthritis-therapeutics-pipeline-analysis/toc-sample

In 2011, Momenta Pharmaceuticals, Inc. collaborated with Shire Plc for the development and commercialization of M923, which is a proposed biosimilar of Humira (adalimumab) but the collaboration was later terminated. In June 2010, F Hoffman-la-Roche announced that RoACTEMRA (known as ACTEMRA outside Europe) is highly effective in improving the signs and symptoms of systemic juvenile idiopathic arthritis, which currently has no licensed treatments. RoACTEMRA is also well tolerated in children with systemic juvenile idiopathic arthritis and has a safety profile similar to adults with rheumatoid arthritis.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the companies having a pipeline of juvenile idiopathic arthritis therapeutics include, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Pfizer, Inc., Novartis AG.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.